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The emergence and global spread of carbapenemase-
producing Enterobacteriaceae is of great concern to 
health services worldwide. These bacteria are often 
resistant to all beta-lactam antibiotics and frequently 
co-resistant to most other antibiotics, leaving very few 
treatment options. The epidemiology is compounded 
by the diversity of carbapenem-hydrolysing enzymes 
and the ability of their genes to spread between differ-
ent bacterial species. Difficulties are also encountered 
by laboratories when trying to detect carbapenemase 
production during routine diagnostic procedures due 
to an often heterogeneous expression of resistance. 
Some of the resistance genes are associated with suc-
cessful clonal lineages which have a selective advan-
tage in those hospitals where antimicrobial use is high 
and opportunities for transmission exist; others are 
more often associated with transmissible plasmids. 
A genetically distinct strain of Klebsiella pneumoniae 
sequence type (ST) 258 harbouring the K. pneumoniae 
carbapenemases (KPC) has been causing epidemics 
of national and international proportions. It follows 
the pathways of patient referrals, causing hospital 
outbreaks along the way. Simultaneously, diverse 
strains harbouring New Delhi metallo-beta-lactamase 
(NDM-1) are repeatedly being imported into Europe, 
commonly via patients with prior medical exposure in 
the Indian subcontinent. Since the nature and scale of 
carbapenem-non-susceptible Entrobacteriaceae as a 
threat to hospital patients in Europe remains unclear, 
a consultation of experts from 31 countries set out to 
identify the gaps in diagnostic and response capacity, 
to index the magnitude of carbapenem-non-suscepti-
bility across Europe using a novel five-level staging 
system, and to provide elements of a strategy to com-
bat this public health issue in a concerted manner.
Introduction
Enterobacteriaceae are among the most abundant com-
mensal microorganisms in humans. They are also the 
most frequent cause of bacterial infections in patients 
of all ages [1]. Their ubiquity and frequent acquisition of 
mobile genetic elements means that their human hosts 
are regularly exposed to new strains with novel genetic 
repertoires – including antibiotic resistance – through 
food and water, or from other animate and inanimate 
sources in the community, hospitals and during travel.
Since the 1950s and 60s – when broad-spectrum anti-
biotics became available for the treatment of Gram-
negative infections – Enterobacteriaceae have acquired 
a growing range of mechanisms to evade these agents. 
In particular, beta-lactam antibiotics such as penicil-
lins and cephalosporins are vulnerable to hydrolysis 
by enzymes called beta-lactamases. In the mid 1970s 
two new beta-lactamase-stable cephalosporin com-
pounds, cefamandole and cefuroxime were marketed 
[2,3], soon followed by related analogues such as cefo-
taxime and ceftriaxone [4]. However, novel extended-
spectrum beta-lactamases (ESBL) soon emerged in 
Enterobacteriaceae, compromising these new com-
pounds [5]. The first hospital outbreaks caused by 
ESBL producers occurred in France in the mid-1980s 
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[6], soon followed by large outbreaks in the United 
States (US) [7,8]. ESBL producers, are now widespread 
worldwide, and often are multidrug-resistant (MDR) 
also to fluoroquinolones and aminoglycosides [9].
A further class of beta-lactam antibiotics, the carbap-
enems, came into clinical use in 1985 [10]. These drugs 
combine exceptional intrinsic antibacterial activity 
with stability to most of the prevalent beta-lactama-
ses, including ESBLs and have become the treatment of 
choice for infections due to the ESBL-producing strains, 
which are increasingly diagnosed in European hospi-
tals. Regrettably, it has become clear that bacteria also 
can acquire carbapenem-hydrolysing beta-lactamases 
(carbapenemases). Such enzymes have emerged in 
various parts of the world, including Europe, the Indian 
subcontinent and the US [11]. In Europe and coun-
tries that were covered by the European Antimicrobial 
Resistance Surveillance System (EARSS, now EARS-
Net) large nationwide outbreaks with carbapenemase-
producing Klebsiella pneumoniae have occurred in 
Israel and Greece, and problems of variable scale are 
unfolding elsewhere in Europe [12-14]. Acknowledging 
the ineffectiveness of almost all alternative antibiotics 
and resistance even to those under development, there 
is a growing awareness that carbapenem-non-suscep-
tible Enterobacteriaceae (CNSE) may thwart the ability 
to treat many life-threatening infections in the future.
The need for a European-wide consultation on this 
matter was recognised during the 2009 annual 
EARSS meeting, and thus a workshop of scientists 
involved in the surveillance of antibiotic resistance in 
Enterobacteriaceae from 31 European countries was 
hosted at the Netherlands’ National Institute for Public 
Health and the Environment (RIVM) on 29 and 30 April 
2010. These scientists already participated in the 
EARSS network and were selected on the basis of their 
expertise in the epidemiology of carbapenem resist-
ance. This workshop aimed (i) to identify the gaps 
in diagnostic and response capacity, (ii) to index the 
magnitude of carbapenem-non-susceptibility across 
Europe using a novel five-level staging system, and (iii) 
to provide elements of a strategy to combat this public 
health issue in a concerted manner 
This report summarises the discussion and outlines the 
complexity of the diagnostic issues and also provides 
information on the epidemiologic situation in European 
countries. The experts’ conclusions aim to solidify 
diverse country-specific experiences into a coherent 
plan of action on surveillance and response to prevent 
the endemic establishment of carbapenemase-produc-
ing Enterobacteriaceae in European hospitals. 
The emergence of carbapenem-non-
susceptible Enterobacteriaceae
In contrast to the increasing prevalence of ESBL-
producing Enterobacteriaceae in Europe [15], CNSE were 
extremely rare during the 1990s and early 2000s, and 
mostly comprised K. pneumoniae, and Enterobacter 
spp. with a permeability deficit that reduced drug 
uptake. This was associated with the inactivation 
of genes coding for outer membrane proteins (in 
K. pneumoniae OmpK35 and OmpK36) that function as 
major porins, allowing solutes to enter the bacterial 
cell [16,17]. This impermeability reduces carbapenem 
susceptibility when combined with ESBLs or AmpC 
beta-lactamases [18] which have trace carbapenem-
hydrolysing activity. Ertapenem is the carbapenem 
most affected by this mechanism, and several cases of 
emerging ertapenem resistance during treatment have 
been reported [19]. Most isolates are unique, with lim-
ited clonal dissemination, perhaps because the imper-
meability is detrimental to the bacteria, making them 
less competitive in the absence of antibiotics.
Carbapenemases, which readily hydrolyse carbapen-
ems, became an international health issue 15 years 
after the introduction of carbapenems, and pose a 
greater threat. They have been described in all four 
classes of beta-lactamases, but the epidemiologically 
most relevant carbapenemases fall into three of these 
[20]: Class B includes the metallo-beta-lactamases 
Table 1
Clinical breakpoints defined by minimum inhibitory concentrations in mg/L for the categories S=susceptible and 
R=resistant according to recommendations of CLSI and EUCAST
Antibiotic compound 
CLSI 2010 EUCAST 2010
Sa R S R
ECOFF 
 for E. coli and K. pneumoniae b
Imipenem ≤1 (≤4) c ≥4 (≥16) ≤2 >8
≤0.5 for E. coli
 ≤1 for K. pneumoniae
Meropenem  ≤1 (≤4) ≥4 (≥16) ≤2 >8 ≤0.125
Ertapenem  ≤0.25 (≤2) ≥1 (≥8) ≤0.5 >1 ≤0.06
Doripenem ≤1 (ND) ≥4 (ND) ≤1 >4 ≤0.12
CLSI: Clinical Laboratory Standards Institute; ECOFF: epidemiological cut-off values; EUCAST: European Committee on Antimicrobial 
Susceptibility Testing; MIC: minimum inhibitory concentration; ND: no data.
a I=intermediate is implied by the values between the S-breakpoint and the R-breakpoint.
b ECOFF for E. coli and K. pneumoniae define the top end of the wildtype distribution; bacteria with MICs ≥ ECOFF have acquired some 
mechanism of resistance.
c Values in parentheses indicate the CLSI breakpoints recommended before June 2010.
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(MBLs) IMP (active on imipenem), and VIM (Verona 
integron-encoded metallo-beta-lactamase) and the 
recently described New Delhi metallo-beta-lactamase 
(NDM-1). In class A, KPC (K. pneumoniae carbapen-
emases) is clinically and epidemiologically the most 
important enzyme, whereas SME (Serratia marcescens 
enzyme), NMC-A/IMI (not metalloenzyme carbapene-
mase/imipenem-hydrolysing beta-lactamase) and GES 
(Guiana extended spectrum) pose minor problems. 
Class D includes the OXA-type carbapenemases which 
are mostly found in Acinetobacter spp., although OXA-
48 occurs in Enterobacteriaceae.
The first transferable carbapenemase identified in 
Gram-negative bacteria was an IMP-like MBL in the Far 
East [21], followed by VIM types in Europe [22]. In early 
2003, VIM-producing Enterobacteriaceae began to 
spread in Greek hospitals [23]. Enterobacteriaceae with 
VIM MBLs have also caused some hospital outbreaks 
in Spain [24] and have been observed sporadically in 
other countries. In some cases, MBL-positive isolates 
were associated with travel, such as importation from 
Greece of K. pneumoniae producing VIM-1 and -2 car-
bapenemases [25]. Since 2008, Enterobacteriaceae 
producing NDM-1 metallo-beta-lactamases have been 
imported repeatedly into Europe from the Indian sub-
continent [26], particularly into the United Kingdom 
(UK) [27] but also to Austria, Belgium, France, Germany, 
the Netherlands, Norway and Sweden. There were also 
importations to Australia, Canada, Japan and the US, 
again largely in patients with recent hospitalisation in 
India, Pakistan or Bangladesh [27,28]. Most were sus-
ceptible only to colistin and, more variably, tigecycline.
NDM-1 producers are mainly K. pneumoniae but also 
include Escherichia coli and Enterobacter spp. Most 
isolates with MBLs, particularly those with NDM 
types, also contain ESBL and acquired ampC genes, 
which makes them resistant to all antibiotics except 
polymyxins, tigecycline and, occasionally, certain 
aminoglycosides. 
K. pneumoniae with KPC carbapenemase were first 
detected in 1996 in North Carolina, then spread along 
the east coast of the US [29,30], and finally across the 
whole country [31], posing a significant threat with 70% 
or higher mortality in bacteraemic patients [32,33]. 
Outside the US, K. pneumoniae with KPC have spread 
widely in Israel and Greece, with outbreaks or isolated 
cases in hospitals in other European countries (below). 
Spread is also occurring in China and Latin America 
[34]. Many K. pneumoniae isolates with KPC enzymes 
belong to a single clonal complex, CC11, and predomi-
nantly to a single sequence type, ST 258, containing 
different variants of the blaKPC gene [13,31,35-37]. Apart 
from K. pneumoniae, KPC enzymes have been found in 
other species of Enterobacteriaceae (e. g. K. oxytoca, 
Enterobacter spp., E. coli) [38,39], and, more recently, 
also in Pseudomonas spp. and Acinetobacter bauman-
nii [40,41]. As with the MBL producers, few treatment 
options remain, although some isolates remain sus-
ceptible to few aminoglycosides (gentamicin, isepa-
micin) as well as to polymyxins (such as colistin) or 
tigecycline. 
OXA-48 was first described in Turkey during an out-
break of K. pneumoniae in Istanbul but has since 
attained international distribution not only among 
K. pneumoniae but also E. coli [42,43]. By 2009, strains 
with OXA-48 enzyme were being reported from the 
Middle East, India, Europe and North Africa [44-46], 
with 25 cases of OXA-48-producing K. pneumoniae in 
the UK alone. Strains with OXA-48 enzyme pose a prob-
lem for detection when using the existing expert rules 
embedded in automated diagnostic test systems as 
they often retain susceptibility to expanded-spectrum 
Figure
Algorithm for interpretation of disk diffusion synergy tests and combined disk tests to detect carbapenem-non-susceptible 
Enterobacteriaceae isolates
K. pneumoniae with MIC to
imipenem ≥1 mg/L (non-wildtypea)
Synergy with APBA but not cloxacicllin Synergy with APBA and cloxacillin Synergy with DPA only
Presence of KPC (or other class
A carbapenemase) Presence of ampC and porin loss Presence of metallo beta-lactamase
APBA: aminophenyl boronic acid (a beta-lactamase inhibitor); DPA: dipicolinic acid (a metal-chelating agent); KPC: K. pneumoniae 
carbapenemase.
a Non-wildtype: an organism harbouring an acquired mechanism of resistance that reduces susceptibility or confers resistance.
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cephalosporins and monobactams but express resist-
ance or decreased susceptibility to carbapenems [47]. 
Carbapenem-non-susceptibility thus displays a very 
diverse picture, in geographical occurrence and enzyme 
types; it also challenges conventional diagnostic abili-
ties because the presence of carbapenemase genes 
does not always translate into clinical resistance as 
defined by the current guidelines and breakpoints, as 
discussed below.
Identification of carbapenem-non-
susceptible Enterobacteriaceae by 
routine susceptibility testing methods
The standard approach for the testing of the antimi-
crobial susceptibility of bacteria in routine diagnostic 
practice is based on measuring bacterial growth in the 
presence of the drugs; either by classical agar disk dif-
fusion assays (Kirby Bauer technique) or with commer-
cially available automated test systems that expose 
bacterial suspensions to a limited range of antimi-
crobial concentrations. The goal is to predict clinical 
outcomes by classifying bacterial isolates as suscep-
tible (S), intermediate (I) or resistant (R) on the basis 
of agreed breakpoints. These breakpoints take into 
account (i) the range of antimicrobial susceptibility in 
a natural bacterial population in the absence of resist-
ance mechanisms (the so-called wildtype distribution), 
(ii) the pharmacology with regards to the time course 
of the drug concentration in the human body (phar-
macokinetics) and the biological effect of the drug at 
these concentrations on the bacteria (pharmacody-
namics), and (iii), whenever available, information on 
clinical outcomes in relation to the minimum inhibitory 
concentration (MIC). Clinical results provide the most 
important information but are also the most difficult to 
acquire and to evaluate [48].
International breakpoint committees such as the 
Clinical Laboratory Standards Institute (CLSI, formerly 
NCCLS) in the US and the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) set and 
modify breakpoints by well defined decision processes 
[49,50]. Importantly, breakpoints as defined by these 
committees are applied by automated diagnostic test 
systems provided by various manufacturers or, after 
conversion into inhibition zone diameters, by agar disk 
diffusion assays. EUCAST also provides crucial guid-
ance for the European Medicines Agency (EMA, for-
merly EMEA) when approving the clinical indications 
for new antimicrobial agents. 
The CLSI modified its clinical breakpoints for carbap-
enems after an expert consultation meeting in January 
2010, reducing their previous values two-fold in order 
to better identify the carbapenemase-producing 
K. pneumoniae (mainly with KPC enzymes) that have 
attained considerable prevalence in US hospitals in the 
last 10 years. EUCAST had previously, in 2008, decided 
to set their breakpoints for the purpose of clinical, i.e. 
therapeutic decision-making and not for optimal detec-
tion of carbapenemase production per se. As a conse-
quence, the clinical breakpoints adopted by EUCAST 
remain one dilution step higher than the modified CLSI 
values (Table 1). Since the updated CLSI breakpoints 
came into use in June 2010, laboratories using these 
standards have been defining susceptibility more con-
servatively than those using EUCAST [51]. 
Both committees recommend reporting susceptibil-
ity testing results at face value, and performing phe-
notypic tests for carbapenemase production only for 
epidemiological or infection control purposes. This will 
have consequences for clinical diagnosis, routine sur-
veillance and public health. 
Clinical laboratory diagnosis
On the basis of available evidence and simulated tar-
get attainment probabilities, EUCAST decided that 
Enterobacteriaceae should be regarded as clinically 
susceptible to imipenem at an MIC of ≤2 mg/L when 
treated with the standard recommended adult dose of 
500 mg four times a day intravenous administration. 
However, the maximum dose of 1g four times a day 
for severe infections was taken into consideration in 
setting the I/R breakpoint >8 mg/L [52]. EUCAST adds 
a note to the breakpoint table that “some strains that 
produce carbapenemase are categorized as suscep-
tible with these breakpoints and should be reported 
as tested, i.e. the presence or absence of a carbapen-
emase does not in itself influence the categorization of 
susceptibility. In many areas, carbapenemase detec-
tion and characterization is recommended or manda-
tory for infection control purposes” [53]. 
The more conservative modified CLSI breakpoint 
addresses the wide demand in the US for simplifica-
tion of phenotypic characterisation of K. pneumoniae 
isolates in the wake of the KPC epidemic. The adop-
tion of the new breakpoints is intended to render the 
modified Hodge test (see below) unnecessary, whereas 
this test was recommended in previous updates to 
the guidelines and had to be used frequently in many 
laboratories. The adoption of these breakpoints by 
the CLSI clearly improves the ability of microbiologi-
cal laboratories to detect carbapenemase-producing 
Enterobacteriaceae, but with an unknown trade-off in 
specificity because more strains with combinations 
of impermeability and ESBL or AmpC are likely to be 
scored as resistant. Moreover, even these break-
points will fail to detect carbapenemase-producing 
Enterobacteriaceae with very low MICs [54]. For clinical 
purposes, a breakpoint-guided therapeutic decision 
algorithm, as favoured by EUCAST, may be sufficient 
if additional molecular events such as mutational porin 
losses that reduce susceptibility during treatment are 
rare enough for bacteriological treatment failures to 
remain uncommon [16,55].
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Routine surveillance and the role of the 
clinical laboratory in public health
The detection of carbapenem resistance within passive 
surveillance systems such as EARS-Net is complicated 
by breakpoint changes. Until recently most laboratories 
within EARS-Net have used the old CLSI breakpoint (S 
if MIC ≤4 mg/L imipenem or meropenem), but reported 
resistance rates will artificially rise when European 
countries/laboratories shift to use the lower EUCAST 
breakpoints routinely in 2010-11. Some laboratories 
may continue with CLSI methodology but by adopting 
the now lower breakpoint prescribed by that organi-
sation will cause a resistance shift in the same direc-
tion. This will lead to some minor discrepancies and it 
remains to be seen if passive surveillance in its current 
format provides sufficient information for infection 
control practitioners and public health experts about 
the extent of the problem at national or international 
levels. 
The contribution of diagnostic laboratories to infec-
tion control and public health is often underappreci-
ated, underfunded and increasingly compromised by 
the streamlining of hospital budgets along tight serv-
ice lines, which often results in the outsourcing of 
diagnostic services [56]. The conundrum of carbapen-
emase-producing Enterobacteriaceae with resistance 
below the radar of routine surveillance but relevant 
enough to cause concern, exposes the lack of consen-
sus on the precise role of microbiological diagnostic 
laboratories in European countries. If isolates with 
lower-level resistance are worth monitoring for infec-
tion control and public health purposes then a simple 
laboratory tool is needed for detection - as simple as 
Etest, or double-disk synergy test (DDST), combination 
disk tests (CDTs) or an expert rule integrated into auto-
mated test systems. 
Detection of carbapenemase-
producing Enterobacteriaceae
Various selective agar media can be used for prelimi-
nary screening and are convenient, especially if they 
are chromogenic, allowing different species or resist-
ance types to be recognised easily [57]. Different 
selective media may be necessary to detect carbapen-
emase-producers with very low carbapenem MICs. The 
addition of a selective agar that contains extended-
spectrum cephalosporins would improve sensitivity in 
the detection of carbapenemases, but would also have 
lower specificity (regular ESBLs are also detected) [58]. 
Comparing growth on agars containing cephalosporins 
and carbapenems might also help in the detection of 
OXA-48 producers. 
For confirmation of carbapenemase production, two 
inexpensive types of tests can be deployed in routine 
as well as reference laboratories:
The first are disk diffusion synergy tests, where 
the potential carbapenemase-producer is tested 
against a carbapenem antibiotic in the presence of 
carbapenemase-inhibiting compounds, including dipi-
colinic acid for MBLs and boronic acid for KPC enzymes 
(Figure). These tests may be performed in disk-approx-
imation, i.e. DDST, or disk-combination, i.e. CDT for-
mats [59]. Combination discs can be prepared locally 
by applying defined amounts of inhibitors to routine 
(meropenem 10 μg) antibiotic disks, or can be pur-
chased [60]. Inhibition, and carbapenemase presence, 
is indicated by zone expansion. The respective inhibi-
tors achieve reasonable specificity for MBLs and KPC 
enzymes [60,61] but no specific inhibitor of OXA-48 
has been identified so far.
The other type of test exploits the leakage of carbap-
enemases from the producer into the surrounding 
agar and its ability to protect susceptible strains on 
the same plate. These tester-reporter assays consist 
of various modifications of the cloverleaf or Hodge 
test. They lack specificity, are difficult to standardise, 
labour-intensive and require a certain degree of expe-
rience to provide confident interpretation of results 
[61,62].
Molecular confirmation tests
Molecular confirmation tests are largely the realm 
of reference laboratories, but can be used for rapid 
screening under epidemic conditions, as demonstrated 
by experiences with faecal screening in Israel [63]. PCR 
assays can be designed to seek different target genes 
in single or multiplex formats with different modes of 
amplicon detection [64]. A commercial one-day test uti-
lising ligase chain reaction and a microarray hybridi-
sation format provides a versatile platform for the 
identification of ESBLs and KPCs [65-67], whilst a new 
test that also detects the genes for AmpC, VIM, IMP and 
NDM-1 enzymes is currently under clinical evaluation.
Carbapenem-non-susceptible 
Enterobacteriaceae in European countries
Although first seen sporadically in the Far East, CNSE are 
now established in Europe. K. pneumoniae is the spe-
cies that most often hosts the resistance and, depend-
ing on the country, assumes various epidemiological 
patterns. The current knowledge of the epidemiology 
of carbapenem-non-susceptible Enterobacteriaceae in 
Europe is summarised below.
Greece 
In Greece, the proportion of imipenem-resistant
K. pneumoniae increased from less than 1% to 20% 
among isolates from hospital wards over five years, 
from 2001 to 2006, and to 50% among isolates from 
intensive care units. In 2002 this type of resist-
ance was reported from only three hospitals but, by 
2008, was present in at least 25 of the 40 hospitals 
participating in the Greek Antimicrobial Resistance 
Surveillance System. The situation was initially caused 
by the spread of the blaVIM-1 cassette among rapidly 
evolving plasmids conferring multiresistance or even 
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pan-resistance to many strains of K. pneumoniae and 
other species of Enterobacteriaceae [68]. The epidemic 
seemed to be polyclonal with no particular clone domi-
nating [69]. In addition, there has been since 2007 a 
rapidly progressing nationwide epidemic of K. pneu-
moniae belonging to ST258 and harbouring KPC-2 and 
SHV-12 genes [70-72; Vatopoulos, unpublished results]. 
This rapid spread could be explained only in part by 
the movement of patients between hospitals. During 
the first few months of 2010 K. pneumoniae strains 
carrying both VIM and KPC enzymes have increasingly 
been identified in Greek hospitals [73].
Israel
In Israel, the first sporadic Enterobacteriaceae with 
KPC-2 carbapenemases were recognised in 2005, 
and comprised Enterobacter (three clones) and E. coli 
(polyclonal). When an increase in K. pneumoniae with 
carbapenemase production was noted in winter of 
2005-06, patients were treated in isolation.  Additional 
diagnostic support (PCR) was suggested but not 
regarded as a cost-effective measure at a time when 
isolates were sporadic and polyclonal. By spring 2006, 
K. pneumoniae with KPC-3 enzyme had become preva-
lent and were found to comprise a single clone (ST258). 
Towards the summer, the caseload had increased 
exponentially and, by the end of 2006, all Israeli hos-
pitals recognised that this strain had reached epidemic 
proportions, as established during an ad hoc meeting 
of the Israeli Infection Control Group in early 2007. 
Following this meeting, a nationwide reporting sys-
tem and control measures were agreed and enacted 
[Carmeli, unpublished results]. 
In March 2007 alone this system recorded 180 cases of 
infection with the ST258 strain but by 2010 its occur-
rence had been reduced and stabilised at about 30 new 
cases per month. Control measures included guidelines 
for screening, isolation and cohort nursing, as well as 
central reporting. Governmental commitment was cru-
cial in supporting hospital management to enforce the 
necessary efforts. 
Poland 
In Poland, MBL-positive Enterobacteriaceae isolates 
(including Serratia marcescens, Enterobacter cloacae, 
Klebsiella spp.), mostly with VIM enzymes, have been 
submitted to the National Medicines Institute in Warsaw 
on 35 occasions since 2006 [Gniadkowski, unpublished 
data]. In May 2008, the first case K. pneumoniae 
ST258 producing KPC-2 and SHV-12 beta-lactamases 
was identified [36]. By the end of 2009, 10 hospitals 
in Warsaw and its surroundings were affected. Each 
reported between one and nine cases, and indicating 
continuing and widening spread. By April 2010, cases 
had been reported from more than 30 hospitals, and 
from six outpatient clinics in 16 cities. The situation is 
still dynamic, with some hospitals seemingly in control 
of the problem whilst others report newly emerging 
cases or have stopped reporting new cases altogether. 
Italy 
In Italy, various Enterobacteriaceae producing VIM 
enzymes have been reported from different regions 
since 2002. These isolates were mostly sporadic [74,75], 
although a single outbreak involving nine patients 
with bloodstream infections arose due to the clonal 
spread of a VIM-1-positive Klebsiella [76]. VIM carbap-
enemases were also found in 36 of 5,500 routinely col-
lected Enterobacteriaceae from acute care hospitals 
and longterm-care facilities in Bolzano (Alto Adige 
region). These isolates also had various other resist-
ance traits (qnrS, blaSHV, blaCTX-M) [77]. In late 2008, the 
first patient with KPC-3-positive K. pneumoniae ST258 
was identified in Tuscany [78], but by early 2010, indis-
tinguishable strains had already been reported from at 
least 11 locations in seven regions, and in some hos-
pital settings they have already reached remarkable 
levels [Rossolini, unpublished results]. Part of this 
spread was associated with patient transfers between 
hospitals. 
Germany 
In Germany, the first outbreak of KPC-2-producing 
K. pneumoniae was reported in 2008 [79,80]. In 2009 
and 2010 two outbreaks with KPC-3-producing K. pneu-
moniae (ST 258) and more than 40 single cases of 
KPC-2/3 in E. coli and K. pneumoniae were observed. 
Identified index patients came from Greece or Israel. 
Regional spread of two distinct multidrug-resistant 
clones over two years due to movement of colonised 
patients between hospitals was shown in Bavaria. 
Moreover several small regional clusters of OXA-48 pro-
ducing K. pneumoniae were identified in 2009 [unpub-
lished results]. Currently, OXA-48 is the most frequent 
carbapenemase in Germany, occasionally in patients 
with connection to Turkey. NDM-1 MBL was identified in 
three E. coli and one Acinetobacter baumannii isolates 
from epidemiologically unrelated patients. 
France 
In France, five monoclonal (single hospital or 
regional) outbreaks with carbapenemase-producing 
Enterobacteriaceae have been reported to health 
authorities since 2004 through the national early warn-
ing system set up at the beginning of the 2000s. In 
three of these outbreaks, involving strains with VIM-1 
or KPC-2 enzymes, the index patient had been trans-
ferred from a Greek hospital [25]. A national programme 
initially designed to contain the spread of vancomycin-
resistant Enterococcus spp. (VRE) was applied to each 
outbreak. This consisted of the rapid implementation 
of a step-by-step containment plan within the affected 
hospital, constant support by local infection control 
teams, regional experts and health authorities, and 
feedback to the medical community at the national 
level. The hospital containment strategy has the fol-
lowing components: (i) stopping transfer of cases and 
contacts within and between hospitals, (ii) cohorting 
separately case and contact patients with dedicated 
healthcare workers, (iii) screening all contact patients, 
and (iv) continuous vigilance through surveillance.
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Hungary
In Hungary, nine K. pneumoniae isolates with non-
susceptibility to carbapenems carrying the KPC-2 car-
bapenemase and SHV-12 ESBL were isolated in three 
centres in the North Eastern Region between October 
2008 and April 2009. All belonged to the ST258 inter-
national clone, were indistinguishable by pulsed-field 
gel electrophoresis (PFGE), and were extensively drug-
resistant. Eight were resistant even to colistin although 
none of the source patients had received this drug, 
which had never been used in any of the affected hos-
pitals in that period. All infected patients died. The 
index patient had a history of hospitalisation in Greece 
[37]. Since then, only one further carbapenemase pro-
ducer has been recorded, a K. pneumoniae ST11 strain 
with VIM-4 enzyme. Interestingly, ST11 is a single-locus 
variant of ST258 and, in Hungary, is commonly seen 
producing the CTX-M-15 ESBL but normally lacking VIM 
genes [81]. 
Spain 
In Spain, VIM-positive Enterobacteriaceae have, as of 
April 2010, been reported from 15 different hospitals, 
IMP-positive strains from another two, and KPC-positive 
Enterobacteriaceae (K. pneumoniae and Citrobacter fre-
undii) from two university hospitals in Madrid [24]. The 
KPC-positive K. pneumoniae strains did not belong to 
the ST258 epidemic clone, but to the ST384 and ST388 
clones. ST388 K. pneumoniae had previously per-
sisted as a carbapenem-susceptible CTX-M-10 beta-
lactamase-producing clone [82]. A structured survey 
in 2008 covering 38 hospitals across Spain, collected 
100,132 isolates of Enterobacteriaceae but only identi-
fied 43 with carbapenemases, mainly VIM types (76%), 
whilst none had KPC types [83]. However, 45 of 245 
carbapenem-non-susceptible Enterobacteriaceae iso-
lates submitted for reference testing between January 
2009 and April 2010 harboured VIM (18%), 15 IMP (6%) 
and 15 were non-carbapenemase-producing strains 
(6%). Two outbreaks involving VIM-1 enzyme-produc-
ing K. pneumoniae were reported at two hospitals in 
Madrid [84] and three small outbreaks were reported 
with carbapenemase-producing Enterobacter spp. [85]. 
United Kingdom
In the United Kingdom NDM seems to de the domi-
nant carbapenemase in Enterobacteriaceae, although 
producers of KPC (increasingly), VIM and OXA-48 car-
bapenemases are also recorded. Patients infected 
with producers of this NDM-1 enzyme have a history 
of hospitalisation on the Indian subcontinent, where 
producer strains of K. pneumoniae, E. coli and other 
Enterobacteriaceae appear to be in wide circulation [27]. 
The dominance of this enzyme in the UK may reflect the 
country’s historic links with India, and the consequent 
population flows to and from the subcontinent. 
Other countries
Import of CNSE by travel has also been detected in 
other countries such as Sweden, Denmark, Norway, 
Finland, and Belgium but the spread was limited, most 
likely thanks to infection control [35,70,86,87].
Proposing a staging scheme for 
the epidemiology of carbapenem 
resistance in European countries 
The experiences reported above suggest that the epi-
demiology of CNSE and especially carbapenemase-pro-
ducing K. pneumoniae in European countries follows 
a pattern typical for hospital-acquired pathogens. 
Initially there is sporadic occurrence and stochastic 
extinction, followed by single hospital outbreaks and 
then spread along the regional and national hospital 
patient referral routes. This also means that hospi-
tals that share the same patients are at a high risk of 
importing colonised or infected individuals, providing 
the sources for the next outbreaks. An intuitive way 
of assessing the degree to which carbapenemase-pro-
ducing Enterobacteriaceae have become established in 
national hospital networks is by indexing these stages, 
and we therefore suggest a simple numerical staging 
system (Table 2). 
Applying this staging scheme and data provided by 
31 reference laboratories for the period up to July 
2010 allowed us to categorise the European countries 
(Table 3). Most countries that reported early stage 
events mentioned documented introduction by travel 
and many were concerned about likely underreporting 
owing to a lack of detection or lack of communication 
(not shown). In clonal outbreak situations, KPC is the 
dominant resistance mechanism, mainly linked to the 
spread of K. pneumoniae international clone ST258.
Conclusions
Care of hospitalised patients throughout Europe is 
threatened by the spread of carbapenem-non-suscepti-
ble Enterobacteriaceae. There are very few therapeutic 
options left to treat these patients, and invasive infec-
tions are associated with disturbingly high mortality 
rates. Little is known about the patient-related risk fac-
tors other than hospitalisation abroad, but the descrip-
tion of outbreaks indicates that producer strains seem 
to benefit from selective advantages in hospitals where 
antimicrobial use is much higher and opportunities for 
transmission more frequent than in the community [88]. 
The association of KPC (and occasionally VIM) enzymes 
with an internationally successful clonal lineage of 
K. pneumoniae indicate that hospital outbreaks are 
local expansions following long transmission chains. 
This is also supported by the frequent international 
introduction of sporadic or primary cases. Consistent 
with the spread of hospital-adapted lineages is the 
repeated observation that outbreaks, especially of 
KPC-positive ST258 K. pneumoniae, follow patient 
referral patterns, with initial local spread and occa-
sional regional and nationwide dissemination. The fact 
that transmission of these clones is mainly confined 
to healthcare settings provides an opportunity for tar-
geted prevention and control. Israel has shown that 
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national consensus approaches with agreed screen-
ing protocols and mandatory reporting can reduce the 
incidence of resistance during a nationwide Klebsiella 
ST258 epidemic. 
Table 3
Expansion of healthcare-associated carbapenem-non-susceptible Enterobacteriaceae in Europe: epidemiological scale and 
stages by country, as of July 2010
Country Stage Epidemiological scale Documented introduction from abroad Dominant class Underreporting
Greece
5 Endemic Yes
KPC/VIM
Israela KPC
Italy
4 Interregional spread Yes KPC
 
Poland Likely 
France
3 Regional spread Yes
KPC
Germany OXA-48/VIM Likely
Hungary KPC Likely
Belgium
2b Independent hospital outbreaks Yes
VIM Likely
Spain KPC/VIM/IMP Likely 
England and Wales NDM
Cyprus
2a Single hospital outbreak
VIM
Netherlands Yes KPC
Norway Yes KPC
Scotland KPC
Sweden Yes KPC
Bosnia Herzegovina
1 Sporadic occurrence
Yes KPC  
Denmark KPC/VIM  
Finland Yes KPC  
Croatia VIM  
Czech Republic Yes VIM/KPC
Ireland KPC Likely
Lithuania ? Likely
Latvia ? Likely
Malta ?  
Portugal KPC Likely
Romania ? Likely
Switzerland KPC
Austria
0 Not reported -
 
Bulgaria Likely
Estonia Likely
Iceland  
Slovenia
a Likelihood of acquisition of CNSE for hospitalised patients low due to containment measures.
Luxembourg and Slovakia were invited to the meeting but did not participate. 
Table 2
Epidemiological scale and stages of nationwide expansion of healthcare-associated carbapenem-non-susceptible 
Enterobacteriaceae
Epidemiological scale Description Stage
No cases reported No cases reported 0
Sporadic occurrence Single cases, epidemiologically unrelated 1
Single hospital outbreak Outbreak defined as more than two epidemiologically related cases in a single institution 2a
Sporadic hospital outbreaks Unrelated hospital outbreaks with independent, i.e. epidemiologically unrelated introduction or different strains, no autochthonous inter-institutional transmission reported 2b
Regional spread More than one epidemiologically related outbreak confined to hospitals that are part of a regional referral network, suggestive of regional autochthonous inter-institutional transmission 3
Inter-regional spread Multiple epidemiologically related outbreaks occurring in different health districts, suggesting inter-regional autochthonous inter-institutional transmission 4
Endemic situation Most hospitals in a country are repeatedly seeing cases admitted from autochthonous sources 5
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Plasmid-borne spread within and between species also 
can occur for blaKPC and is the dominant mode of dis-
semination for NDM and VIM genes. This epidemiology 
is more complex and harder to interrupt, complicating 
national intervention strategies. 
Regardless of whether it is the spread of the strain or 
the gene that is dominant, the key to success in prevent-
ing the establishment of carbapenemase-producing 
Enterobacteriaceae is early detection and good diagnos-
tic practice. Recent decisions by international break-
point committees are taking into account the fact that 
MICs for carbapenemase-producing Enterobacteriaceae 
may represent a continuum close to or even overlap-
ping with the top end of the wildtype distribution. Even 
the most conservative breakpoints will not assign all 
carbapenemase-producing Enterobacteriaceae into the 
non-susceptible class and may also classify strains 
with porin loss and presence of ESBL or AmpC lactama-
ses as resistant. The epidemiological consequences of 
underdetection of carbapenemase producers with MICs 
in the sub-breakpoint range are still unclear. Current 
MIC breakpoints are set to guide treatment, but more 
clinical studies on the effectiveness of carbapenems 
against carbapenemase-producing Enterobacteriaceae 
with relatively low MICs are needed, as are simple, 
inexpensive, phenotypic tests to recognise produc-
ers, irrespective of MIC, with adequate specificity and 
sensitivity. Molecular confirmation tests are useful for 
reference purposes and are conveniently rapid when 
screening faecal samples during outbreaks. 
Hospital outbreaks, defined as more than two epide-
miologically related cases, need to be brought to the 
attention of regional health authorities as well as to all 
hospitals receiving referred patients. A close collabo-
ration between the microbiological laboratory and the 
local and regional infection control team(s) is decisive 
for the prevention and control at local hospital level. 
Areas for improvement 
The workshop identified ten areas for improvement, 
displayed in the list below. Areas 1 to 6 recognise the 
need for better laboratory-based detection and surveil-
lance, whereas areas 7 to 10 address infection control 
and clinical research needs. 
Area 1: Ad hoc case ascertainment 
with existing laboratory capacity
•	  All routine diagnostic laboratories must test the 
susceptibility of all isolated Enterobacteriaceae, 
from all anatomical sites in each patient, with at 
least one carbapenem, specifically imipenem or 
meropenem. Resistance to ertapenem is more 
prone to arise through combinations of imperme-
ability and AmpC or ESBL activity, especially in 
Enterobacter spp., reducing specificity. 
•	  Laboratories should inform their local infection 
control teams of their tentative findings and report 
non-susceptibility of blood culture isolates to the 
national EARS-Net data manager. 
•	  They should forward isolates to national reference 
centres for confirmation and molecular testing. 
Area 2: Standardisation of 
detection and reporting
•	  Agreement needs to be achieved on the minimum 
test requirements for detection and data report-
ing of CNSE within the national and international 
reporting structures. 
•	  A panel of highly characterised CNSE isolates 
should be made available to all laboratories for 
test calibration. 
•	  For laboratories that wish to participate in national 
or international surveillance initiatives (EARS-Net) 
participation in regular external quality assess-
ment exercises should be mandatory, and should 
include carbapenemases. 
•	  An improvement to EARS-Net would be a recom-
mendation to report carbapenem-non-susceptibil-
ity rather than resistance, similar to the reporting 
of susceptibility for penicillin in Streptococcus 
pneumoniae. 
•	  A list of national reference and other centres with 
the required skills to identify molecular mecha-
nisms of carbapenem resistance should be avail-
able to all clinical laboratories in each country. 
Area 3: Need for consistent capacity 
building of reference diagnostics 
•	  Workshops should be organised to train reference 
laboratory personnel on a set of phenotypic and 
genetic test methods to allow exhaustive charac-
terisation of carbapenemase-producing isolates 
submitted by routine diagnostic laboratories. 
•	  The workshops shall follow a ‘training the trainers 
approach’ in order to provide European reference 
laboratories with the means to train peripheral 
laboratories. 
•	  This will increase the coherence of reporting and 
strengthen national surveillance and diagnostic 
capacity. 
•	  The training should ideally take place in an endemic 
country to provide course participants with hands-
on experience of the workload, and to appraise the 
challenges in task management, procurement and 
costing. 
Area 4: Need for structured surveys to 
determine sensitivity and specificity of defined 
breakpoints or other inclusion criteria
•	  A group of experts shall develop the protocol for a 
structured survey aiming to optimise a diagnostic 
algorithm to identify CNSE with a high degree of 
accuracy and a minimum number of false positives. 
•	  This will require agreement on a set of selection 
criteria (e.g. overall resistance profile and a mero-
penem MIC ≥ 0.5 mg/L) [54]. 
•	  Furthermore the sampling frame needs to be 
defined, a sample size estimated, and a design for 
roll-out to all European countries developed. 
•	  The results should not only provide the best sen-
sitivity and specificity but also reveal the true 
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prevalence of CNSE in a representative cross-sec-
tional sample of the population. 
Area 5: Need for a harmonised 
typing tool/initiative
•	  Molecular typing of CNSE is complex due to the 
multifaceted nature of their spread. Plasmid spread 
occurs among different species, and repeated 
introduction to Europe via travel may challenge 
typing laboratories with a near-random sample of 
strains circulating in other countries. 
•	  Nevertheless, the potential for rapid spread of sin-
gle lineages, as seen with K. pneumoniae ST258 
in Greece, Israel and recently in Poland and Italy, 
underscores the need for rapid assessment of the 
spread of such clones, as these are of particular 
public health importance. 
•	  It is therefore highly desirable to invest in the 
development of typing systems with a better reso-
lution for strains and plasmids. 
•	  Only sequence-based data will provide the robust-
ness and portability required for modern decen-
tralised approaches. 
•	  In any case the practicability and applicability of 
typing methods must be considered. 
Area 6: Need for central data collection on 
the dissemination and introduction of strains 
with particular public health importance
•	  With harmonised test methods, detection, typing 
and reporting criteria comes the ability to net-
work the data collected at local and national levels 
into international databases that would be freely 
accessible and searchable for hospitals and public 
health agencies. 
•	  This will allow for early recognition of temporal-
spatial tends, outbreaks and importation by travel. 
Systems of this kind have been developed for 
infections caused by Legionella pneumophila and 
Staphylococcus aureus [89,90]. 
•	  We believe that the spread of CNSE and the con-
sequent treatment problems create an urgent need 
for the construction of a similar IT platform to pre-
vent these traits from becoming endemic in the 
European region. 
Area 7: Need for guidelines for graded 
approaches to infection control
•	  Appropriate infection control measures need to be 
guided by epidemiological staging, which can be 
defined at national level as described above (See 
Tables 2 and 3). 
•	  If CNSE have not yet been reported, highly sensi-
tive detection criteria coupled with an early warn-
ing system and preparedness should be in place. 
•	  For countries with sporadic outbreaks, infection 
control teams should be trained to implement 
measures to contain spread at the local level fol-
lowing a ready-to-use stepwise approach. 
•	  Reporting the occurrence and the outcome of out-
breaks will inform health authorities on the epide-
miology and success of national strategies. 
•	  Countries with advanced-stage epidemiology 
should resort to screening and isolation in accord-
ance with epidemiological and geographic extent 
of the cases reported. Such policies were success-
ful in Israel. 
•	  In such settings, national health authorities should 
inform other EU Member States on the prevail-
ing epidemiology, so that safe policies for patient 
transfer from their countries can be established. 
Area 8: Antibiotic policy
•	  Antibiotic overuse and misuse are the main factors 
that select multidrug-resistant organisms such as 
CNSE from the commensal flora. 
•	  Diversification and de-escalation of antibiotic 
treatment, particularly carbapenems, fluoroqui-
nolones but also third-generation cephalosporins, 
are key to the response to the CNSE emergence. 
•	  This should include guidelines on antibiotic use for 
non-severe infections (e.g. urinary tract infections) 
and an intensified dialogue with prescribers across 
Europe. 
Area 9: Treatment and clinical research
•	  Clinical trials about the effectiveness of remaining 
alternative treatment strategies for CNSE infec-
tions are urgently needed. 
•	  Incentives need to be provided for the develop-
ment of new antibiotics active against CNSE. 
Area 10: Political commitment
•	  Importantly, the political commitment at national 
governmental as well as European level is critical. 
•	  The European Centre for Disease Prevention 
and Control should play a role in harmonising 
European surveillance, detection and identification 
strategies. 
•	  The World Health Organization (WHO) should 
address this issue in a proactive manner glo-
bally, possibly through the International Health 
Regulations which are an international legal instru-
ment that is binding for 194 countries across the 
globe, including all the WHO member states. 
•	  Their aim is to help the international commu-
nity prevent and respond to acute public health 
risks that have the potential to cross borders and 
threaten people worldwide [91].
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